MDT Medtronic plc
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1613103 · Fiscal year ends 04/24
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY12.3%
TTM EPS YoY12.2%
Revenue 3-yr CAGR6.0%
Net income 3-yr CAGR13.1%
Margins
Gross margin65.0%
Operating margin18.1%
Net margin13.9%
FCF margin16.3%
EBITDA margin23.5%
Returns
ROE10.7%
ROA5.7%
ROIC (approx.)7.1%
Asset turnover0.41x
Leverage & solvency
Liabilities / assets45.5%
Debt / equity0.56x
Current ratio2.07x
Interest coverage9.37x
Cash quality & payout
Operating cash flow / net income1.54x
Accruals ratio-3.0%
Payout ratio69.8%
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-04-24 | FY20252025-04-25 | FY20242024-04-26 | FY20232023-04-28 | FY20222022-04-29 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B |
| Cost of revenue | $12.72B | $11.63B | $11.22B | $10.72B | $10.14B |
| Gross profit | $23.64B | $21.91B | $21.15B | $20.51B | $21.54B |
| R&D expense | $2.87B | $2.73B | $2.73B | $2.70B | $2.75B |
| SG&A expense | $11.78B | $10.85B | $10.74B | $10.41B | $10.29B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B |
| Interest expense | $715.00M | $729.00M | $719.00M | $636.00M | $553.00M |
| Pretax income | $6.14B | $5.63B | $4.84B | $5.36B | $5.52B |
| Income tax | $1.30B | $936.00M | $1.13B | $1.58B | $456.00M |
| Net income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B |
| EBITDA | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B |
| EPS (basic) | 3.75 | 3.63 | 2.77 | 2.83 | 3.75 |
| EPS (diluted) | 3.73 | 3.61 | 2.76 | 2.82 | 3.73 |
| Dividends declared per share | 2.84 | 2.80 | 2.76 | 2.72 | 2.52 |
| Weighted avg. shares (diluted) | 1.29B | 1.29B | 1.33B | 1.33B | 1.35B |
| Banking | |||||
| Net interest income | $383.00M | $511.00M | $597.00M | $386.00M | $186.00M |
| Balance sheet | |||||
| Cash & equivalents | $1.95B | $2.22B | $1.28B | $1.54B | $3.71B |
| Short-term investments | $7.27B | $6.75B | $6.72B | $6.42B | $6.86B |
| Receivables | $6.64B | $6.51B | $6.13B | $6.00B | $5.55B |
| Inventory | $5.95B | $5.48B | $5.22B | $5.29B | $4.62B |
| Current assets | $24.79B | $23.81B | $21.93B | $21.68B | $23.06B |
| PP&E, net | $7.42B | $6.84B | $6.13B | $5.57B | $5.41B |
| Goodwill | $42.59B | $41.74B | $40.99B | $41.42B | $40.50B |
| Intangibles | $10.15B | $11.67B | $13.22B | $14.84B | $15.60B |
| Total assets | $93.03B | $91.68B | $89.98B | $90.95B | $90.98B |
| Current liabilities | $11.66B | $12.88B | $10.79B | $9.05B | $12.39B |
| Short-term debt | $1.79B | $2.87B | $1.09B | $20.00M | $3.74B |
| Long-term debt | $26.17B | $25.64B | $23.93B | $24.34B | $20.37B |
| Total debt | $27.96B | $28.52B | $25.02B | $24.36B | $24.11B |
| Total liabilities | $42.96B | $43.42B | $39.56B | $39.28B | $38.26B |
| Shareholders' equity | $49.46B | $48.02B | $50.21B | $51.48B | $52.55B |
| Net debt | $26.01B | $26.30B | $23.74B | $22.82B | $20.40B |
| Shares outstanding | 1.28B | 1.28B | 1.31B | 1.33B | 1.33B |
| Cash flow statement | |||||
| Operating cash flow | $7.33B | $7.04B | $6.79B | $6.04B | $7.35B |
| Capital expenditure | $1.90B | $1.86B | $1.59B | $1.46B | $1.37B |
| Free cash flow | $5.43B | $5.18B | $5.20B | $4.58B | $5.98B |
| Investing cash flow | -$2.93B | -$1.94B | -$2.37B | -$3.49B | -$1.66B |
| Financing cash flow | -$4.75B | -$4.36B | -$4.45B | -$4.96B | -$5.34B |
| Depreciation & amortization | $2.96B | $2.86B | $2.65B | $2.70B | $2.71B |
| Stock-based compensation | $457.00M | $429.00M | $393.00M | $355.00M | $359.00M |
| Dividends paid | $3.64B | $3.59B | $3.67B | $3.62B | $3.38B |
| Share buybacks | $1.03B | $3.23B | $2.14B | $645.00M | $2.54B |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.